Hussman Strategic Advisors Inc. Acquires New Position in TransMedics Group, Inc. $TMDX

Key Points

• Hussman Strategic Advisors opened a new position in TransMedics by acquiring 14,700 shares (~$1.79M) in Q4, joining other institutions (Goldman Sachs now holds 507,510 shares); institutional ownership is 99.67%.
• Company insiders have been net sellers, disposing of 16,205 shares (~$2.35M) over the last 90 days (including Nicholas Corcoran and Anil Ranganath), and now own 6.90% of the company.
• Analysts have raised price targets (Oppenheimer $175, Needham $174, Piper $160), leaving a consensus rating of "Moderate Buy" with a target of $152.33, while the stock trades around $100 (market cap ≈ $3.45B).

Hussman Strategic Advisors Inc. acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 14,700 shares of the company's stock, valued at approximately $1,788,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TMDX. Royal Bank of Canada grew its holdings in TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock valued at $1,788,000 after buying an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock valued at $1,314,000 after buying an additional 868 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock valued at $34,145,000 after buying an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company's stock valued at $1,059,000 after buying an additional 938 shares in the last quarter. Finally, M&T Bank Corp purchased a new position in TransMedics Group during the 2nd quarter valued at about $209,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Down 0.8%

Shares of NASDAQ TMDX opened at $100.01 on Friday. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of 20.41 and a beta of 2.07. The business has a 50-day moving average of $117.36 and a 200-day moving average of $125.98. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. TransMedics Group, Inc. has a 12 month low of $89.10 and a 12 month high of $156.00.

Insiders Place Their Bets

In other TransMedics Group news, insider Nicholas Corcoran sold 2,966 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the completion of the sale, the insider owned 29,831 shares of the company's stock, valued at $4,150,088.72. This represents a 9.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anil P. Ranganath sold 864 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the completion of the sale, the insider directly owned 13,091 shares of the company's stock, valued at approximately $1,821,219.92. This represents a 6.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,205 shares of company stock valued at $2,353,002 over the last 90 days. Company insiders own 6.90% of the company's stock.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of recent analyst reports. Oppenheimer lifted their target price on TransMedics Group from $150.00 to $175.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. Piper Sandler lifted their target price on TransMedics Group from $140.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Needham & Company LLC lifted their target price on TransMedics Group from $166.00 to $174.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $114.00 to $149.00 and gave the company a "neutral" rating in a report on Wednesday, February 25th. Finally, Stifel Nicolaus boosted their price objective on TransMedics Group from $115.00 to $130.00 and gave the stock a "hold" rating in a report on Monday, March 9th. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus price target of $152.33.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.